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Introduction
DNA damage blocks the progression of replicative DNA poly-
merases and causes stalled replication forks at S phase. Persistent 
stalled replication forks collapse and cause genomic instabil-
ity or cell death (Kolodner et al., 2002). In Saccharomyces 
 cerevisiae, stalled replication forks are resolved either by 
  bypassing DNA damage with translesion synthesis (TLS) poly-
merases or by template switching to the nascent strand of sister 
chromatid (Smirnova and Klein, 2003; Ulrich, 2005). The se-
lection of these pathways is regulated through the modifi  cation 
of proliferating cell nuclear antigen (PCNA), a homotrimeric 
complex that encircles DNA strands and functions as a 
loading dock for DNA polymerases as well as various DNA 
 repair  machinery.
PCNA is monoubiquitinated at the lysine 164 (K164) by 
the ubiquitin ligase (E3) yRad18 with the ubiquitin-conjugating 
enzyme (E2) yRad6/Ubc2 after the cells are treated with a low 
concentration (0.02%) of the alkylating agent methyl methane-
sulfonate (MMS; Hoege et al., 2002). Monoubiquitinated PCNA 
switches the replicative DNA polymerase δ to nonessential 
polymerases specialized for TLS (Fig. 1 A; Friedberg et al., 
2005). After the treatment of yeast cells with MMS, the same 
monoubiquitinated lysine residue of PCNA is further modifi  ed 
with a noncanonical lysine 63 (K63)–linked polyubiquitin chain 
by yRad5 (E3) along with the yUbc13–yMms2 (E2 and E2 vari-
ant) heterodimer complex (Hoege et al., 2002). This modifi  ca-
tion of PCNA presumably promotes the error-free mode of 
bypass, which is thought to use a template-switch type of re-
combination through reversal of stalled forks (Lawrence, 1994; 
Ulrich, 2005). However, nothing is known about molecular 
mechanisms downstream from PCNA polyubiquitination.
Mammalian PCNA also undergoes monoubiquitination af-
ter a low dose of MMS (0.02%) and UV irradiation, and mono-
ubiquitinated PCNA preferentially binds to TLS polymerases 
(Kannouche et al., 2004; Friedberg et al., 2005). So far, no evident 
PCNA polyubiquitination has been observed in mammals. 
  Furthermore, even though homologues of yRad18 (RAD18), 
yRad6 (HHR6A and HHR6B), yUbc13 (UBC13), yMms2 (MMS2/
UEV2), and downstream TLS polymerases have been identifi  ed 
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ifferential modiﬁ   cations of proliferating cell nu-
clear antigen (PCNA) determine DNA repair path-
ways at stalled replication forks. In yeast, PCNA 
monoubiquitination by the ubiquitin ligase (E3) yRad18 
promotes translesion synthesis (TLS), whereas the lysine-
63–linked polyubiquitination of PCNA by yRad5 (E3) 
promotes the error-free mode of bypass. The yRad5-
  dependent pathway is important to prevent genomic in-
stability during replication, although its exact molecular 
mechanism is poorly understood. This mechanism has 
remained totally elusive in mammals because of the lack 
of apparent RAD5 homologues. We report that a putative 
tumor suppressor gene, SHPRH, is a human orthologue of 
yeast RAD5. SHPRH associates with PCNA, RAD18, and 
the ubiquitin-conjugating enzyme UBC13 (E2) and 
promotes methyl methanesulfonate (MMS)–induced PCNA 
polyubiquitination. The reduction of SHPRH by stable 
short hairpin RNA increases sensitivity to MMS and 
enhances genomic instability. Therefore, the yRad5/
SHPRH-dependent pathway is a conserved and funda-
mental DNA repair mechanism that protects the genome 
from genotoxic stress.
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(Koken et al., 1991; Hofmann and Pickart, 1999; Johnson et al., 
1999; Masutani et al., 1999; Tateishi et al., 2000), no apparent 
RAD5 homologues have been discovered. Therefore, it has been 
controversial whether the mammalian error-free mode of bypass 
exists, and PCNA regulation through differential ubiquitinations 
is a conserved and fundamental mechanism in mammals.
SHPRH is a putative tumor suppressor gene encoding a 
large protein of 1,683 amino acids with various predicted func-
tional domains, including SWI2/SNF2 and RING domains (Fig. 
1 B; Sood et al., 2003). The human SHPRH gene was mapped 
to chromosome 6q24, which has been suggested to contain tu-
mor suppressor genes. Four point mutations in the SHPRH gene 
were identifi  ed in melanoma and ovarian cancer–derived cell 
lines, although roles of SHPRH in cancer development have 
been largely unexplored (Sood et al., 2003).
In an effort to investigate whether mammals have a yeast 
Rad5–like pathway that prevents genomic instability, we identi-
fi  ed SHPRH as a human RAD5 orthologue. We demonstrate that 
SHPRH has conserved biochemical properties with yeast Rad5 
and suppresses genomic instability by promoting K63-linked 
polyubiquitination of PCNA.
Results and discussion
Human SHPRH promotes noncanonical 
K63-linked polyubiquitination of PCNA
Yeast Rad5 is a member of the SWI2/SNF2 family of helicases 
with the E3 activity (Johnson et al., 1992). A unique structural fea-
ture of yRad5 is that the RING domain for its E3 activity is embed-
ded between the conserved motifs IV and V of the SWI2/SNF2 
domain (Fig. 1 B). To identify human proteins with this unique 
domain structure, we performed a SMART search (http://smart.
embl-heidelberg.de/) and identifi  ed a putative tumor suppressor 
gene, SHPRH. SHPRH and yRad5 show 45.5 and 36.4% identities 
Figure 1.  Human SHPRH and yeast Rad5 share the domain structure. 
(A) Differential modiﬁ  cations of PCNA determine DNA repair pathways. 
R18, Rad18; R5, Rad5; R6, Rad6; 13, Ubc13; 2, Mms2. (B) Schematic 
representation of human (Hs) SHPRH and yeast (Sc) Rad5. SWI2/SNF2 
(subdomains I, Ia, II, III, IV, V, and VI) and RING ﬁ  nger domains are indi-
cated. Multiple alignments of RING ﬁ  nger domains of human (Hs), rat (Rn), 
mouse (Mm), zebraﬁ  sh (Dr) SHPRH homologues, ﬁ  ssion yeast (Sp) rad8 
(a Rad5 homologue), and budding yeast (Sc) Rad5. Dots indicate the con-
served cysteines and histidine. The cysteine mutated in this study (C1432) 
is indicated with an asterisk.
Figure 2.  SHPRH is a functional orthologue of 
yeast Rad5. (A) SHPRH promotes PCNA poly-
ubiquitination. HEK 293T cells were transfected 
with plasmids expressing 0.5 μg HA-ubiquitin 
(HA-Ub), 0.5 μg FLAG-PCNA, 2.0 μg SHPRH-
myc-His, 100 ng RAD6-HA, 50 ng UBC13-HA, 
50 ng UBC13(C87A)-HA, and 50 ng MMS2-
HA in the combinations indicated. Lysates 
were immunoprecipitated with an anti-FLAG 
antibody, and ubiquitinated PCNAs were de-
tected by an anti-HA antibody. Total PCNAs 
were probed with an anti-FLAG antibody. 
PCNA-Ub
1 and PCNA-Ub
N indicate mono- and 
polyubiquitinated PCNAs, respectively. Mono- 
and diubiquitinated PCNAs are marked with 
single and double asterisks, respectively. Ex-
pression of SHPRH and E2s was analyzed by 
blotting lysates with speciﬁ  c  anti-epitope  tag 
antibodies. (B) E3 ligase activity of SHPRH for 
PCNA polyubiquitination is perturbed by a 
mutation in the conserved cysteine of the RING 
domain (C1432A). (C) HEK 293T cells were 
transfected as in A, except using ubiquitin mu-
tants (left), PCNA-K164R mutant (middle), or 
lentivirus-infected 293T cells (right). The dot 
represents the IgG heavy chain. Lanes 4 and 5 
of the top panel were exposed longer than 
lanes 6 and 7. (D) RAD18 and SHPRH cooper-
ate to promote PCNA polyubiquitination. Cells 
were transfected as indicated with the same 
amounts of plasmids as in A, and endogenous 
PCNA was immunoprecipitated with an anti-
PCNA antibody.HUMAN SHPRH PROMOTES PCNA POLYUBIQUITINATION • MOTEGI ET AL. 705
and 62.1 and 47.3% similarities in the SWI2/SNF2 and RING do-
mains, respectively, but have little homology in other sequences 
(Fig. 1 B and Fig. S1, available at http://www.jcb.org/cgi/content/
full/jcb.200606145/DC1). SHPRH also contains predicted linker-
histone and PHD-fi  nger domains, which are not found in yRad5. 
Just like mammalian RAD18, which shares even higher sequence 
similarity with yRAD18 (Tateishi et al., 2000), SHPRH expression 
could not rescue the UV sensitivity of the rad5 strain (Fig. S2).
To test whether SHPRH is a functional orthologue of 
yRad5, we examined whether SHPRH could polyubiquitinate 
PCNA. The overexpression of HA-tagged ubiquitin (HA-Ub), 
FLAG-tagged PCNA (FLAG-PCNA), and myc-His–tagged 
SHPRH (SHPRH-myc-His) in human embryonic kidney (HEK) 
293T cells induced mono- and polyubiquitinations of PCNA 
(Fig. 2 A, lane 5). PCNA polyubiquitination by SHPRH was 
further enhanced by UBC13–MMS2 (Fig. 2 A, lane 7) but not 
by RAD6 (lane 6) or UBC13 with the C87A mutation, which 
inactivates the E2 activity of UBC13 (lane 8). In contrast, 
RAD18 exclusively induced PCNA monoubiquitination with 
RAD6 (Fig. S3 A, lanes 6 and 7, available at http://www.jcb.
org/cgi/content/full/jcb.200606145/DC1). Enhancement of 
PCNA monoubiquitination by SHPRH may be caused by com-
petition between SHPRH and the deubiquitin enzyme USP1, 
which removes monoubiquitin from PCNA (Huang et al., 2006). 
To clarify the role of the RING domain in SHPRH, we created 
two proteins: one with a mutation at the conserved cysteine 
1432 in the RING domain (C1432A) and the other with a dele-
tion of the entire RING domain at the C terminus (∆RING). 
Both mutants showed reduced levels of PCNA polyubiquitina-
tions (Fig. 2 B, lane 4; and Fig. S3 B), suggesting a role of the 
RING domain of SHPRH. The remaining levels of PCNA ubiq-
uitinations observed in these mutants imply that SHPRH mu-
tants may be able to “recruit” or “nucleate” endogenous SHPRH 
or other E3 ligases. Supporting the specifi  city of overexpressed 
SHPRH to PCNA, SHPRH expression did not affect the basal 
polyubiquitination level of His6-c-JUN, a nuclear protein modi-
fi  ed with a lysine 48–linked polyubiquitin chain by several ubiq-
uitin ligases, such as SCF
Fbw7 (Nateri et al., 2004; Fig. S3 C).
Conserved roles of SHPRH as a human 
Rad5 orthologue
To determine whether SHPRH polyubiquitinates the conserved 
K164 of PCNA, which is also targeted by yRad5, PCNA (either 
wild type or K164R mutant) was immunoprecipitated and the 
level of mono- and polyubiquitinations was analyzed. PCNA 
with the K164R mutation was defective in mono- and polyubiq-
uitinations (Fig. 2 C). Furthermore, the SHPRH-promoted poly-
ubiquitination of PCNA was reduced by the overexpression of the 
ubiquitin(K63R) mutant but was enhanced by the ubiquitin(K48R) 
mutant (Fig. 2 C). We therefore concluded that SHPRH functions 
with the UBC13–MMS2 complex to modify the K164 of PCNA 
with a noncanonical K63-linked polyubiquitin chain in vivo.
Previous yeast studies suggested that the monoubiquitination 
of PCNA by yRad18 precedes polyubiquitination by yRad5 (Hoege 
et al., 2002). It is consistent with genetic observations that yRAD18 
is epistatic to yRAD5 after exposure to various DNA-damaging 
agents (Johnson et al., 1992; Ulrich and Jentsch, 2000; Motegi 
et al., 2006). Notably, stable knockdown of RAD18 by short hairpin 
RNA (shRNA) substantially reduced SHPRH-mediated PCNA 
polyubiquitination (Fig. 2 C). Furthermore, coexpression of 
RAD18 and RAD6 with SHPRH and UBC13–MMS2 synergis-
tically promoted the polyubiquitination of endogenous PCNA 
(Fig. 2 D). These results clearly indicate that the PCNA monoubiq-
uitination by RAD18–RAD6 and polyubiquitination by SHPRH–
UBC13–MMS2 are sequential, rather than competitive, events.
SHPRH interacts with PCNA, UBC13, 
and RAD18 and self-multimerizes
Yeast Rad5 interacts with PCNA, yUbc13, and yRad18 and self-
multimerizes (Ulrich and Jentsch, 2000). We observed that SHPRH 
physically interacted with GST-fused PCNA (wild type or K164R 
mutant) and GST-UBC13, but not with GST-MMS2, GST-RAD6, 
or GST alone (Fig. 3, A and B). The interactions between the 
PCNA(K164R) mutant and SHPRH or RAD18 suggest that the 
Figure 3.  SHPRH physically interacts with PCNA, UBC13, and RAD18 and 
multimerizes. (A and B) SHPRH associates with PCNA and UBC13 in vitro. 
SHPRH-FLAG was pulled down with GST-fused PCNA (wild type or K164R 
mutant; A) or with GST-fused E2s (B) and analyzed by blotting with an anti-
FLAG antibody. RAD18-FLAG was also pulled down with GST-PCNA (A). 
(C and D) SHPRH associates with UBC13 in vivo. SHPRH-myc-His (C) or 
SHPRH-FLAG (D) was coexpressed with wild-type UBC13-HA, UBC13(CA)-
HA, or MMS2-HA in the combinations indicated. Anti-myc (C) or anti-HA 
(D) immunoprecipitates were blotted with an anti-HA (C) or anti-FLAG (D) 
antibody. Note that the level of SHPRH is enhanced in the presence of wild-
type UBC13 and, to a lesser extent, UBC13(CA). SHPRH showed a weak 
but reproducible interaction with UBC13(CA). Blots with anti–α-tubulin or 
anti-GFP serve as loading or transfection control, respectively. (E and F) 
SHPRH interacts with RAD18 and self-multimerizes in vivo. In F, cell lysates 
expressing SHPRH-FLAG and SHPRH-myc-His were immunoprecipitated 
with anti-myc antibody and blotted with an anti-FLAG antibody. Normal 
IgG antibody was used for control.JCB • VOLUME 175 • NUMBER 5 • 2006  706
ubiquitination of PCNA is not essential for these interactions. 
SHPRH interacted with UBC13 and weakly with UBC13(C87A) 
in vivo (Fig. 3, C and D). Although structural studies predicted that 
the interaction site on UBC13 with RING domains is distinct from 
the cysteine C87 (VanDemark et al., 2001), C87 may affect this 
interaction in vivo. In addition, we observed an increased level of 
SHPRH protein in cells coexpressing wild-type UBC13 and, to a 
lesser extent, UBC13(C87A), suggesting the stabilization of 
SHRPH through the complex formation with UBC13. We also 
identifi  ed the self-association of SHPRH and the interaction be-
tween SHPRH and RAD18 by coimmunoprecipitation experi-
ments (Fig. 3, E and F). These observations demonstrate that 
SHPRH has interaction features similar to yRad5.
SHPRH suppresses genomic instability 
through PCNA polyubiquitination
To investigate the biological signifi  cance of PCNA polyubiqui-
tination in mammalian cells, we transfected HEK 293T cells 
with low amounts of plasmids that express HA-ubiquitin and 
FLAG-PCNA, with or without SHPRH-myc-His, and treated 
with various DNA-damaging agents. No apparent changes in 
PCNA polyubiquitination were detected after treating cells with 
30 J/m
2 UV or 0.3 mM of the DNA cross-linking agent mitomy-
cin C (MMC; Fig. 4 A). In contrast, PCNA polyubiquitination 
was induced after treating cells with 0.01% MMS (Fig. 4 A, 
lane 7). MMS-induced PCNA polyubiquitination was strongly 
enhanced by the additional expression of SHPRH. We also no-
ticed that the signals of SHPRH in the cell extracts were re-
duced only when cells were treated with MMS (Fig. 4 A, lane 8), 
implying that SHPRH was redistributed to the insoluble 
(chromatin bound) fraction. MMS treatment of HCT116 human 
colon carcinoma cells (without any transfections) also showed 
endogenous PCNA polyubiquitination in a dose-dependent 
manner (Fig. 4 B). To examine the cell cycle specifi  city of 
PCNA polyubiquitination, we treated cells arrested in G1 phase 
or 4 h after release from the G1 arrest with MMS. We observed 
a somewhat substantial level of PCNA polyubiquitination in un-
treated cells in G1 phase, but not in S phase (Fig. 4 C, lanes 1 
and 3). Importantly, PCNA polyubiquitination was most effi  -
ciently induced in mid–S phase (Fig. 4 C, lane 4).
Mutations in genes in the yRad5 pathway cause genomic 
instability and increased cell sensitivity to various DNA-
  damaging agents (Smirnova and Klein, 2003; Stelter and 
Ulrich, 2003; Smith et al., 2004; Motegi et al., 2006). To deter-
mine whether reduced expression of SHPRH could cause simi-
lar cellular phenotypes, we transduced HCT116 cells with 
lentiviral vectors that express two different SHPRH-interfering 
shRNAs (constructs B or C; Fig. 5 A). SHPRH-silenced cells 
(by construct C) showed a substantial reduction in MMS-
  induced PCNA polyubiquitination compared with control (Fig. 
5 B, lane 4). All three clones with reduced SHPRH expression 
showed higher sensitivity to MMS than wild type or the two 
control clones infected with an empty lentivirus (Fig. 5 C). In 
contrast, SHPRH-silenced cells showed no substantial sensitiv-
ity to UV mimetic 4-nitroquinoline 1-oxide (4-NQO), MMC, or 
γ-irradiation (unpublished data). Moreover, SHPRH-silenced 
clones (B2 and C4) showed a greater number of chromosome 
breaks than did wild type after 0.01% MMS treatment (Fig. 5, 
D and E). Notably, the levels of reduction of SHPRH expression 
(Fig. 5 A) were well correlated with their levels of sensitivity to 
MMS and the frequencies of chromosome breaks (Fig. 5, A, D, 
and E). These observations suggest that SHPRH is involved in 
MMS-induced DNA-damage responses.
Accumulating evidence suggests that DNA damage by-
pass followed by PCNA modifi  cations is important for sup-
pressing genomic instability and cancers. For example, the 
overexpression of HHR6B was implicated in the chromosomal 
instability phenotypes of human breast cancer cells (Shekhar 
et al., 2002). The targeted disruptions of the RAD18 or REV3L 
gene in either mouse embryonic stem cells or mouse embryonic 
fi  broblasts, respectively, increased genomic instability, includ-
ing sister chromatid exchange, homologous recombination, and 
illegitimate recombination (Tateishi et al., 2003; Wittschieben 
et al., 2006). Mutations of XPV, which encodes a TLS poly-
merase η, were found in cancer-prone xeroderma pigmentosum 
variant syndrome (Johnson et al., 1999; Masutani et al., 1999). 
Figure 4.  PCNA polyubiquitination is induced by MMS. (A) HEK 293T 
cells transfected with plasmids expressing 0.2 μg HA-ubiquitin (Ub) and 
0.2 μg FLAG-PCNA with or without 0.6 μg SHPRH-myc-His were treated 
with 30 J/m
2 UV, 0.3 mM MMC, or 0.01% MMS for 2 h. Anti-FLAG immuno-
precipitated PCNA was analyzed with an anti-HA antibody. (B) MMS treat-
ment induces polyubiquitination of endogenous PCNA. HCT116 cells were 
treated with the indicated doses of MMS for 2 h. Immunoprecipitated 
PCNA was analyzed with an anti-ubiquitin (P4D1) antibody. (C) HCT116 
cells in G1 (lanes 1 and 2) or S phase (lanes 3 and 4) were treated with 
0.01% MMS for 2 h. A polyubiquitinated species of PCNA was detected 
with anti-polyubiquitin (FK2) antibody.HUMAN SHPRH PROMOTES PCNA POLYUBIQUITINATION • MOTEGI ET AL. 707
Our observations prove that the regulatory mechanisms of 
PCNA through differential modifi  cations by RAD18 and yRad5/
SHPRH are fully conserved and constitute a fundamental mecha-
nism to prevent genomic instability throughout evolution.
Materials and methods
Cell culture, reagents, and antibodies
HEK 293T and HCT116 cells were cultured in DME and McCoy’s media 
supplemented with 10% fetal bovine serum, respectively. Commercially 
available anti-PCNA (PC10), anti-ubiquitin (P4D1), anti-polyubiquitin 
(FK2), anti-myc (9E10), anti-HA (12CA5), anti-FLAG (M2), anti-V5 antibod-
ies, and anti-RAD18 (K-15) were used. Polyclonal anti-SHPRH antibody 
was previously described (Sood et al., 2003). MMS, MMC, and mimosine 
were purchased from Sigma-Aldrich.
Construction of various expression plasmids
Full-length cDNA of human SHPRH was obtained by PCR with IMAGE 
clones (available from GenBank/EMBL/DDBJ under accession nos. 
AI888407 and AA255592) and RACE-PCR products as templates. 
cDNA encoding human RAD18, PCNA, MMS2 (UEV2), and RAD6 
(HHR6B) were obtained from Mammalian Genome Collection (RAD18, 
MHS1010-52750;  PCNA, MHS1011-58526; MMS2, MHS1011-
62471;  HHR6B, MHS1011-62750). Expression plasmids were 
  constructed by subcloning each cDNA into pcDNA3.1-myc-His, p3X-
FLAG-CMV, or pGEX-6P-1. UBC13(wild type or C87A)-HA–expressing 
plasmids were gifts from D. Bohmann (European Molecular Biology 
Laboratory, Heidelberg, Germany) and J. Kehrl (National Institute of 
  Allergy and Infectious Diseases, Bethesda, MD), respectively. Point 
  mutations in the RING ﬁ   nger domain of SHPRH(C1432A) and in 
PCNA(K164R) were introduced by using an in vitro mutagenesis method 
(QuikChange; Stratagene).
Coimmunoprecipitation and GST pull-down assays
For coimmunoprecipitation assay, HEK 293T cells were transfected with 
various combinations of expression plasmids using FuGENE 6 transfection 
reagent (Roche) and lysed in the TNE buffer (50 mM Tris-HCl, pH 7.5, 100 
mM NaCl, 0.5% NP-40, 1 mM EDTA, 8% glycerol, 0.5 mM DTT, 50 mM 
NaF, 1 mM PMSF, 1 μg/ml aprotinin, and 1 μg/ml leupeptin). For the 
GST pull-down assay, various GST fusion proteins were expressed in 
  Escherichia coli strain BL21 (DE3)-RIL (Stratagene) and puriﬁ  ed  using 
  glutathione–Sepharose beads (GE Healthcare). 20 μg of GST fusion pro-
teins were used for pulling down SHPRH-FLAG or RAD18-FLAG expressed 
in HEK 293T cells.
Generation of lentivirus-mediated stable knockdown cells
SHPRH-silencing vectors were constructed by cloning the target sequences 
of 5′-T  T  C  A  A  T  G  C  C  C  T  C  C  T  A  C  A  C  -3′ (construct B) and 5′-A  G  T  G  T  C  C  A  T  C  C  T  T-
T  C  C  A  T  -3′ (construct C) into the lentivirus-based expression vector pLL3.7 
(a gift from V. Parijs, Massachusetts Institute of Technology, Cambridge, MA). 
RAD18-silencing lentivirus vector was purchased from Open Biosystems. 
Lentivirus packaging plasmids were gifts from F. Candotti (National Human 
Genome Research Institute, Bethesda, MD). Lentivirus-infected cells were 
selected by the expression of GFP (SHPRH) or by puromycin (RAD18). The 
expression level of SHPRH was examined by Western blot or by RT-PCR 
with primers 5′-G  A  G  C  A  A  C  T  C  T  G  A  T  C  A  T  C  T  C  T  C  C  A  A  G  -3′ and 5′-G  A  T  A  G  A-
G  A  A  G  T  C  G  A  A  C  C  C  A  C  C  A  G  T  G  -3′. Primers used for amplifying ACTIN as 
a control were 5′-G  C  T  C  G  T  C  G  T  C  G  A  C  A  A  C  G  G  C  T  C  -3′ and 5′-C  A  A  A  C  A  T-
G  A  T  C  T  G  G  G  T  C  A  T  C  T  T  C  T  C  -3′. SHPRH-silenced clones B2, B11 (construct B), 
and C4 (construct C) were used in this study.
Detection of MMS-induced PCNA polyubiquitination, sensitivity assay, 
and chromosome breakage analysis
HCT116 cells were treated with MMS for 2 h, washed with PBS, and lysed 
in RIPA buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 0.1% Triton 
X-100, 0.5 mM DTT, 50 mM NaF, 1 mM PMSF, 1 μg/ml aprotinin, and 
1 μg/ml leupeptin). In some experiments, cells were treated with 0.5 mM 
mimosine for 20 h. For measuring MMS sensitivity, SHPRH-knockdown 
cells were treated with increasing concentrations of MMS for 1 h, washed 
with PBS three times, replated onto 6-well plates at deﬁ  ned cell densities, 
and cultured for 10 d. Colonies grown from the surviving cells were 
counted and expressed as a survival fraction (%) compared with untreated 
cells as 100%. For analyzing MMS-induced chromosomal breaks, SHPRH-
knockdown cells were treated with 0.01% MMS for 1 h, washed with PBS 
three times, and cultured for 24 h. At least 100 metaphase spreads from 
each clone were analyzed.
Online supplemental material
Fig. S1 shows moderate homology between the SWI2/SNF2 domains in 
SHPRH and yeast Rad5. Fig. S2 shows that SHPRH expression in the yeast 
rad5 strain could not complement UV sensitivity. Fig. S3 shows that RAD18 
and RAD6B induced exclusive monoubiquitination of PCNA, the reduced 
activity of SHPRH(∆RING) for PCNA polyubiquitination, and that SHPRH did 
not promote polyubiquitination of c-JUN. Online supplemental material is 
available at http://www.jcb.org/cgi/content/full/jcb.200606145/DC1.
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Figure 5.  SHPRH suppresses MMS-induced 
genomic instability. (A) Expression level of 
SHPRH in individual clones carrying an inte-
grated SHPRH-shRNA vector was analyzed by 
RT-PCR (top) and Western blot with anti-SHPRH 
antibody (bottom). (B) SHPRH-silenced cells 
show a reduced level of MMS-induced PCNA 
polyubiquitination. HCT116 cells with control 
(vector) or SHPRH-silencing (shRNA) lentivirus 
were treated with 0.01% MMS for 2 h. (C) The 
reduced expression of SHPRH sensitizes cells 
to MMS. Three independent shRNA clones 
were treated with increasing concentrations of 
MMS, and serially diluted cells were plated. 
Surviving colonies were counted and quanti-
ﬁ   ed. Doses of MMS for 10% survival are 
0.0145% (wild type [wt]), 0.0110% (B2), 
0.0090% (C4), and 0.0085% (B11). (D and E) 
Reduction of SHPRH enhances chromosome 
breaks by MMS. Metaphase chromosomes 
were analyzed 24 h after a 1-h treatment of 
different clones with 0.01% MMS. (D) One ex-
ample from each clone is shown. (E) Noticeable 
chromosome breakages per cell were quanti-
ﬁ  ed from 100 metaphases per each clone.JCB • VOLUME 175 • NUMBER 5 • 2006  708
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